Everything below concerns MOD GRF(1-29). We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-06-11. Numbers and descriptions here follow the published literature rather than marketing material.
Two forms circulate in research settings and are frequently confused. One carries the drug affinity complex and is often written as CJC-1295 with DAC; the other lacks that group and is usually called modified GRF(1-29). The two share the same core sequence but differ sharply in how long they persist in blood. Products labelled only as CJC-1295 normally refer to the version carrying the complex. Documentation that omits the distinction leaves the intended molecule ambiguous.
CJC-1295 is a synthetic peptide built as a long-acting analogue of growth hormone-releasing hormone. Its backbone matches the first twenty-nine residues of the natural human hormone, with four amino acid substitutions added to slow enzymatic breakdown. A reactive maleimide group, commonly termed the drug affinity complex, allows the peptide to attach to circulating albumin after administration. That albumin attachment keeps the molecule in the bloodstream for an extended period instead of being cleared within minutes.
The compound emerged from work at a Canadian biotechnology firm in the early 2000s. Early human studies examined its effect on growth hormone and insulin-like growth factor 1 in healthy volunteers and in people with HIV-associated fat redistribution. Reports described sustained increases in both markers after a single injection. Development did not advance to regulatory approval, and the clinical programme was later discontinued. The molecule is now encountered mainly as a research chemical rather than a marketed medicine.
Two principal forms appear in the literature and in research supply. One carries a drug affinity complex, a maleimide-based group that forms a covalent bond with circulating albumin. This linkage slows clearance and produces a long-lasting elevation of peptide levels. The other form lacks that group and is often labeled MOD GRF(1-29). It has a much shorter circulation time. Both variants retain the same core receptor-binding sequence. Reported half-lives differ substantially between the two.
At the pituitary, the peptide binds the growth hormone-releasing hormone receptor on somatotroph cells. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone. Somatostatin and other hypothalamic signals modulate this response. Negative feedback from insulin-like growth factor 1 also influences output. The same regulatory architecture operates with the native hormone. Whether the synthetic analog alters feedback dynamics over repeated exposure remains an open question. Most published receptor work uses cell models rather than intact human systems.
CJC-1295 is a synthetic peptide belonging to the growth hormone-releasing hormone analog family. It comprises twenty-nine amino acid residues derived from the N-terminal region of natural GHRH. The molecule incorporates several non-natural substitutions that increase resistance to enzymatic degradation. These modifications extend its activity compared with the native hormone fragment. Researchers use it to study pituitary growth hormone secretion in laboratory and clinical settings. This compound is distinct from native GHRH in its stability profile.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C152H252N44O42 | Cited for the form without the drug affinity complex |
| Molecular weight | About 3368 Da | Reported value for modified GRF(1-29) |
| Appearance | White to off-white powder | Lyophilised solid as usually supplied |
| Solubility | Soluble in water and polar solvents | Clarity depends on purity and salt content |
| Typical storage | -20 C or below, dry | Protect from light and repeated warming cycles |
Peptide degradation proceeds mainly through hydrolysis, oxidation of methionine, and deamidation of asparagine or glutamine residues. The maleimide group on the albumin-binding variant can also react with thiols or hydrolyze in aqueous media. Because these pathways accelerate with temperature and pH extremes, handling conditions strongly influence measured stability. Stability data in the public literature are limited and often generated under differing conditions, so general statements about shelf life should be read as approximate.
Research material is normally supplied as a freeze-dried powder in sealed vials. In that state the peptide is comparatively robust, but prolonged exposure to warmth, moisture, or light accelerates degradation. Storage at minus twenty degrees Celsius or lower, with desiccant and protection from light, is the commonly described practice. Vials should be allowed to reach room temperature before opening to limit condensation on the powder. Moisture uptake during handling is a recognized source of variability in later measurements.
The albumin-binding version stays in circulation for days, because covalent attachment to serum albumin shields the peptide from rapid filtration and degradation. Reported half-lives for this form fall in the range of several days. The version without the linker is cleared in minutes, with estimates often near thirty minutes in animal work. These figures come from small studies and vary with assay method, species, and route, so they are best read as approximate rather than fixed constants.
Studies in this area generally track growth hormone pulses, insulin-like growth factor 1 concentrations, and occasionally body composition endpoints. Most published human data come from early, small trials, and questions about long-term effects remain open. Whether repeated exposure alters pituitary responsiveness over time is not settled. Analytical work relies on immunoassays for the hormones and on mass spectrometry for the peptide itself, because the two measurements answer different questions.
Binding of the peptide to the growth hormone-releasing hormone receptor on pituitary somatotrophs triggers a G protein coupled cascade that raises cyclic AMP and opens calcium channels. The result is greater secretion of growth hormone into the bloodstream. Because the peptide acts at the same receptor as the natural hypothalamic hormone, its effect is amplified pulse size rather than an entirely separate release pathway. Receptor binding alone does not determine the response, since somatostatin tone and other inputs modulate the final output.
The Confederation of British Industry (CBI) announces it is suspending all key activities until June after a number of companies, including John Lewis & Partners, BMW and Virgin Media O2, withdraw from the organisation following the emergence of allegations of sexual assault and rape. Leaders of the Communication Workers Union recommend their members working for Royal Mail accept a pay offer worth 10% over the next three years. The climate protest group Extinction Rebellion begins four days of demonstrations in central London to coincide with Earth Day, and which they describe as "The Big One". 22 April – Sunak holds an emergency COBRA meeting to discuss the evacuation of British nationals caught up in the Sudan conflict. 23 April Diane Abbott is suspended from the Labour Party after writing a letter in The Observer in which she downplays racism against Irish people, Jews, and Travellers. Sunak confirms that British diplomats and their families have been evacuated from Sudan in a "complex and rapid" operation. The Emergency Alerts service is tested by the government at 3pm BST. An estimated 80% of smartphones are believed to be compatible to receive the alert, but around 7% of those do not receive it. Many people on the Three network report that the alert failed to appear on their phone, while others do not receive it because their phone is switched to aeroplane mode or they have disabled emergency alerts. 2023 London Marathon: Sifan Hassan wins the women's race, while Kelvin Kiptum wins the men's event and breaks the course record.
=== Gas chromatography === After extracting rocks or live samples with organic solvents, tetrahymanol, gammacerane, and other lipids can be separated using gas chromatography. This technique separates molecules based on their polarity and size, which both inversely affect boiling point. As a compound's boiling point increases, it spends more time as a condensed liquid in the bonded liquid stationary phase of the GC column. More volatile compounds will partition into the gaseous mobile phase and have a short elution time. Before injection onto the chromatographic column, the alcohol substituent on tetrahymanol is acetylated with acetic anhydride, allowing it to volatilize and enter the GC.
The Fukushima nuclear accident in 2011 reinforced the need for proper safety management and the derivation of safety indicators regarding the frequency of errors and incorrect actions by personnel, i.e., the human factor. The Nuclear Safety Commission of Japan (Japanese: 原子力安全委員会) was a body of scientists that advised the Japanese government on nuclear safety issues. The commission was established in 1978, but was dissolved after the Fukushima nuclear disaster on September 19, 2012, and replaced by the Genshiryoku Kisei Iinkai (Japanese: 原子力規制委員会, lit. 'Nuclear Regulatory Committee'). It is an independent agency (gaikyoku, "external office") of the Japanese Ministry of the Environment that regulates and monitors the safety of Japan's nuclear power plants and related facilities. As a result of the Chernobyl nuclear disaster in 1986, the IAEA coined the term "safety culture" for the first time in 1991 to draw attention to the importance of human and organizational issues for the safe operation of nuclear power plants. After this nuclear disaster, the sand in children's playgrounds in Germany was removed and replaced with uncontaminated sand to protect children who were most vulnerable to radioactivity. Some families temporarily left Germany to escape the fallout. Infant mortality increased significantly by 5% in 1987, the year after Chernobyl. In total, 316 more newborns died that year than statistically expected.
As HVEC shifted into conglomerate model, its subsidiary Electronized Chemicals Corporation began producing in-house products with HVEC devices. By 1960, ECC had introduced product lines in heat-shrink tubing, shrink wrap, and cross-linked wiring. In the late 1970s, piggybacking on research projects led by John Trump, HVEC expanded into environmental applications of electron beam technology. In 1980, the company received a $1 million contract from Miami-Dade County for electron beam equipment to disinfect wastewater before discharge to sanitary landfills. The company also received contracts to expand a prototype sewage sludge treatment plant for the Massachusetts Metropolitan District Commission and to develop an electron beam system for poultry feed disinfection.
Sources: en.wikipedia.org
=== Dehydrated and freeze-dried === Dehydrated or freeze-dried meals come in raw and cooked forms. Products are usually air-dried or frozen, then dehydrated (freeze-dried) to reduce moisture to the level where bacterial growths are inhibited. The appearance is very similar to dry dog pellets. The typical feeding methods include adding warm water before serving. There is some concern of nutrients, such as vitamins, being lost during the dehydration process. Specialty small batches sold through specialty or online stores generally consist of some form of cooked meat, ground bone, pureed vegetables, taurine supplements, and other multivitamin supplements. Some pet owners use human vitamin supplements, and others use vitamin supplements specifically engineered for dogs.
== Industrial sources == β-carotene is industrially made either by total synthesis (see Retinol § Industrial synthesis) or by extraction from biological sources. Natural sources primarily include carrot, crude palm oil, and microalgae (such as Dunaliella salina), and genetically-engineered microbes. The synthetic path is low-cost and high-yield.
Glucose enters the β-cells through the glucose transporters, GLUT 2. At low blood sugar levels little glucose enters the β-cells; at high blood glucose concentrations large quantities of glucose enter these cells. The glucose that enters the β-cell is phosphorylated to glucose-6-phosphate (G-6-P) by glucokinase (hexokinase IV) which is not inhibited by G-6-P in the way that the hexokinases in other tissues (hexokinase I – III) are affected by this product. This means that the intracellular G-6-P concentration remains proportional to the blood sugar concentration. Glucose-6-phosphate enters glycolytic pathway and then, via the pyruvate dehydrogenase reaction, into the Krebs cycle, where multiple, high-energy ATP molecules are produced by the oxidation of acetyl CoA (the Krebs cycle substrate), leading to a rise in the ATP:ADP ratio within the cell. An increased intracellular ATP:ADP ratio closes the ATP-sensitive SUR1/Kir6.2 potassium channel (see sulfonylurea receptor). This prevents potassium ions (K+) from leaving the cell by facilitated diffusion, leading to a buildup of intracellular potassium ions. As a result, the inside of the cell becomes less negative with respect to the outside, leading to the depolarization of the cell surface membrane. Upon depolarization, voltage-gated calcium ion (Ca2+) channels open, allowing calcium ions to move into the cell by facilitated diffusion. The cytosolic calcium ion concentration can also be increased by calcium release from intracellular stores via activation of ryanodine receptors.
Sources: en.wikipedia.org
It is a synthetic peptide analogue of growth hormone-releasing hormone. Four substitutions in its sequence make it more resistant to enzymatic degradation than the natural hormone. In the version carrying a drug affinity complex, the peptide binds albumin and remains in circulation for days.
No regulatory agency has approved CJC-1295 for clinical use. Human trials were conducted in the 2000s, but the development programme was discontinued before any marketing application succeeded. Material sold today is offered as a research chemical, and its purity depends on the supplier.
Sermorelin is an unmodified fragment of growth hormone-releasing hormone and is cleared quickly. CJC-1295 contains substitutions that resist breakdown, and the form with a drug affinity complex persists much longer. Both act at the same receptor but differ substantially in duration of action.
It is a synthetic peptide modeled on growth hormone-releasing hormone. The molecule is used in research on pituitary growth hormone secretion. It differs from the natural hormone through several stabilizing substitutions.